Table 3 Half-maximal inhibitory concentration (IC₅₀) data (Fig. 6B) establishing potency order for HCT-116 cells.
From: Liposomal co-delivery of β-carotene and doxorubicin for enhanced colorectal-cancer therapy
Formulation | IC₅₀ (µg mL⁻1) ± SD | Relative potency vs vehicle ( ×) |
|---|---|---|
Empty liposomes | 1,159.8 ± 7.0 | – |
Liposomal β-carotene | 951.8 ± 18.8 | 1.22 |
Liposomal doxorubicin | 614.0 ± 1.8 | 1.89 |
Liposomal β-carotene–doxorubicin | 618.9 ± 5.8 | 1.87 |
Free β-carotene | 960.6 ± 13.6 | 1.21 |
Free doxorubicin | 610.9 ± 11.4 | 1.90 |
